Karen Cruey
Psychiatry · Las Vegas, NVNPI 1437180478
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 30.2% of the total. Among psychiatry clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 185 payments — averaging $43.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$993
- Alkermes, Inc.$779
- Tris Pharma Inc$695
- Corium, LLC$283
- plus $1K from 12 others
What the payments were for
- Food & beverage$7,973100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 40 | $2,407 |
| Otsuka America Pharmaceutical, Inc. | 28 | $1,575 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $993 |
| Alkermes, Inc. | 10 | $779 |
| Tris Pharma Inc | 29 | $695 |
| Corium, LLC | 5 | $283 |
| Vanda Pharmaceuticals Inc. | 3 | $278 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $176 |
| Supernus Pharmaceuticals, Inc. | 4 | $168 |
| E.r. Squibb & Sons, L.L.C. | 1 | $146 |
| Lundbeck LLC | 8 | $127 |
| Axsome Therapeutics, Inc. | 1 | $121 |
| Neos Therapeutics, LP | 6 | $82 |
| Vertical Pharmaceuticals, LLC | 3 | $46 |
| Arbor Pharmaceuticals, Inc. | 2 | $37 |
| Adlon Therapeutics L.p. | 2 | $30 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Cardiovascular Systems Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$2,017
- ARISTADA$1,397
- LYBALVI$1,390
- REXULTI$1,097
- CAPLYTA$479
- ARISTADA INITIO$349
- Fanapt$249
- Azstarys$236
- ABILIFY MAINTENA$231
- COBENFY$146
- QELBREE$125
- Quillichew ER$125
- Quillivant$125
- Dyanavel XR$125
- Auvelity$121
How this compares
$7,976 in reported general payments places this provider in the 90th percentile of 243 psychiatry providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 20 | $30,895 |
| TrintellixVortioxetine Hydrobromide | 52 | $25,194 |
| AdderallDextroamphetamine/Amphetamine | 33 | $14,190 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 40 | $3,198 |
| Ziprasidone Hcl | 11 | $2,628 |
| Fluvoxamine Maleate | 43 | $2,066 |
| Buspirone Hcl | 32 | $1,722 |
| Divalproex Sodium | 13 | $1,688 |
| Memantine Hcl | 14 | $1,603 |
| Quetiapine Fumarate | 76 | $1,159 |
| Hydroxyzine Hcl | 27 | $1,144 |
| Alprazolam | 67 | $874 |
| Gabapentin | 72 | $758 |
| Olanzapine | 44 | $619 |
| Duloxetine Hcl | 42 | $521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Adderall | $176 | $39,38485 claims |
| AbbVieVraylar | $2,407 | $30,89520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 243 psychiatry providers in Nevada.
Other psychiatry in Las Vegas
- Jelena KunovacLas Vegas$1.2M
- John AnooshianLas Vegas$836K
- Sam ZandLas Vegas$410K
- Aaron RitterLas Vegas$173K
- Mustafa RawafLas Vegas$166K
- Dylan WintLas Vegas$86K
- Mujeeb ShadLas Vegas$55K
- Dax WolfordLas Vegas$29K
- Faisal SubaLas Vegas$15K
- Ejine OkoroaforLas Vegas$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.